University of Arizona Cancer Center

A new experimental pill, daraxonrasib, nearly doubled survival time for patients with advanced pancreatic cancer compared to chemotherapy in a clinical trial. The drug targets a mutated protein present in over 90% of pancreatic cancer cases and showed fewer severe side effects, with patients reporting better quality of life.

A novel pill, daraxonrasib, nearly doubled survival time for patients with advanced pancreatic cancer compared to chemotherapy in a study of 500 patients. The drug, which targets a mutated protein common in pancreatic cancer, showed fewer severe side effects and is being considered a new standard of care. The FDA plans to expedite its review, and the Food and Drug Administration is allowing expanded access for eligible patients.

A new experimental pill, daraxonrasib, nearly doubled survival time for patients with advanced pancreatic cancer compared to chemotherapy, with fewer severe side effects. The drug, which targets a mutated protein common in pancreatic cancer, is being fast-tracked for FDA review and has shown improved quality of life for patients.

A clinical trial of daraxonrasib, a pancreatic cancer drug developed by Revolution Medicines, showed patients lived nearly twice as long as those receiving standard chemotherapy. Results were presented at the American Society of Clinical Oncology meeting and published in the New England Journal of Medicine.